Collegium Pharmaceutical, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a COLL research report →
Companywww.collegiumpharma.com
Collegium Pharmaceutical, Inc. , a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment.
- CEO
- Vikram Karnani
- IPO
- 2015
- Employees
- 357
- HQ
- Stoughton, MA, US
Price Chart
Valuation
- Market Cap
- $1.11B
- P/E
- 14.65
- P/S
- 1.39
- P/B
- 3.51
- EV/EBITDA
- 2.72
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 60.68%
- Op Margin
- 23.85%
- Net Margin
- 9.41%
- ROE
- 26.74%
- ROIC
- 10.51%
Growth & Income
- Revenue
- $780.57M · 23.62%
- Net Income
- $62.87M · -9.13%
- EPS
- $1.98 · -7.48%
- Op Income
- $187.08M
- FCF YoY
- 61.11%
Performance & Tape
- 52W High
- $50.79
- 52W Low
- $28.34
- 50D MA
- $34.38
- 200D MA
- $39.64
- Beta
- 0.76
- Avg Volume
- 552.38K
Get TickerSpark's AI analysis on COLL
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 18, 26 | Freund John Gordon | sell | 20 |
| May 14, 26 | Lurker Nancy | other | 8,741 |
| May 14, 26 | Paya Carlos V | other | 8,741 |
| May 15, 26 | Freund John Gordon | other | 8,700 |
| May 15, 26 | Freund John Gordon | sell | 4,127 |
| May 14, 26 | Freund John Gordon | other | 8,741 |
| May 15, 26 | Freund John Gordon | other | 8,700 |
| May 14, 26 | BOHLIN GAREN G | other | 8,741 |
| May 14, 26 | Glancy Donovan Michael | other | 17,482 |
| May 14, 26 | Balice-Gordon Rita J. | other | 8,741 |
Our COLL Coverage
We haven't published any research on COLL yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate COLL Report →